Clinical-stage biotechnology company uncovering autoprotective antibodies from disease-resilient individuals to discover and develop novel therapeutics. Its Resiliome platform integrates a large antibody database derived from disease-resilient individuals with advanced AI and lab validation to identify and characterise protective antibodies.
Investment Rounds
Capital activity and funding progression
Frequently Asked Questions
Where is Alchemab Therapeutics located?
Alchemab Therapeutics is located in Cambridge, United Kingdom.
What industries does Alchemab Therapeutics operate in?
Alchemab Therapeutics operates in the following industries: biotechnology, life sciences, artificial intelligence, drug discovery.
When was Alchemab Therapeutics founded?
Alchemab Therapeutics was founded on 2026-07-09.
How much total funding has Alchemab Therapeutics raised?
Alchemab Therapeutics has raised a total of $25,000,000.
Who are the investors in Alchemab Therapeutics?
The investors in Alchemab Therapeutics are: British Business Bank.
What is the primary focus of Alchemab Therapeutics?
Alchemab Therapeutics is a clinical-stage biotechnology company that harnesses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from individuals who show unexpected resilience to hard-to-treat diseases such as cancer and neurodegenerative conditions.
What is the Resiliome platform used by Alchemab Therapeutics?
The Resiliome platform is a proprietary AI-enabled tool that integrates a vast database of over half a billion human antibody sequences with machine learning and lab-based protein science to identify protective antibodies found only in resilient individuals.
Is Alchemab Therapeutics a public or private company?
Alchemab Therapeutics is a private, clinical-stage biotechnology company.
Who are the key figures behind Alchemab Therapeutics?
Alchemab Therapeutics was founded in 2019. Its executive leadership includes CEO and co-founder Dr. Jane Osbourn, while its scientific founders include Rachel Bashford-Rogers, Ben Larman, Ruth McKernan, and Uri Laserson.
What is the status of the lead asset for Alchemab Therapeutics?
The lead asset, ATLX-1282, is a first-in-class antibody therapeutic in clinical development for amyotrophic lateral sclerosis (ALS). The program has been licensed to Eli Lilly and Company for further development and commercialization following successful Phase I study initiation.